Join our annual Boston Oncology Drug Discovery symposium, this year focusing on the novel technologies and trends driving new cancer therapies.

Cancer research is constantly being reinvented, as we learn more about human and tumor biology and how they interact with and influence each other. With sustained innovation in preclinical oncology tools and therapeutic approaches, our improved understanding can continue to be translated into new targeted agents and immunotherapies with improved patient benefits.

The symposium will bring together preclinical oncology and immuno-oncology R&D teams from biotech and pharmaceutical companies to facilitate cross discipline discussions on current techniques, and how you can move forward with future approaches.

Discussion Topics Include

• Optimizing TIL profiling to investigate relationships between I/O model tumor microenvironment and immunotherapy treatment outcomes
• Novel targets in DNA repair pathways, including for PARP inhibitors
• The evolution of current preclinical models such as PDX for evaluation of next generation therapies

Presentation & Speakers

John MacDougall Senior Director, I/O Discovery and Translational Biology, BioXcel Therapeutics BXCL701: An Inhibitor of Dipeptidyl Peptidases and its Role in Activation of Innate Immunity and Anticancer Immunotherapy

Henry Li Senior Vice President, Global Scientific Research and Innovations, Crown Bioscience Patient-Derived Xenografts (PDX) as a Discovery and Translational Platform for Targeted and I/O Strategies

Keith Mikule Senior Director, Research and Early Development, TESARO Targeting Cancers with DNA Repair: Beyond BRCA

Annie An Associate Director, Global Biomarker Core, Crown Bioscience TIL Analysis of Syngeneic Mouse Tumors

Shanthi Ganesh Associate Director, Preclinical Oncology, Dicerna Pharmaceuticals Targeting β-catenin to Potentiate Cancer Immunotherapy